GSK SS MRCLS
Research type
Research Study
Full title
A Multicenter Observational Study of Patients Receiving Systemic Treatment for Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
IRAS ID
306781
Contact name
Alexander Thomas John Lee
Contact email
Sponsor organisation
GlaxoSmithKline group of companies
Duration of Study in the UK
0 years, 6 months, 31 days
Research summary
Synovial Sarcoma (SS) and Myxoid round cell liposarcoma (MRCLS) are rare conditions with limited treatment options available; in the absence of a specific treatment for advanced SS or MRCLS, treatment practices may vary based on local practices and guidelines.
To date, the natural history, real-world treatment patterns, and outcomes among patients with SS and MRCLS has not been well-characterized across countries. To aid in the development of advanced SS and MRCLS investigational treatments, it is critical to understand the natural history of advanced SS and MRCLS in the context of real-world practices as well as the evolution of treatment pathways and how these influence real-world clinical outcomes.
The goal of this real-world, multicenter, observational study is to describe the natural history of advanced (metastatic or unresectable) SS and MRCLS as well as the evolving patterns of care in the treatment of advanced (metastatic or unresectable) SS and MRCLS across countries.REC name
London - Fulham Research Ethics Committee
REC reference
22/PR/0149
Date of REC Opinion
8 Mar 2022
REC opinion
Further Information Favourable Opinion